The triglyceride-lowering effect of supplementation with dual probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032: Reduction of fasting plasma lysophosphatidylcholines in nondiabetic and hypertriglyceridemic subjects

• Published in: Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2015-08, Vol.25 (8), p.724-733
• Main Authors: Ahn, H.Y, Kim, M, Ahn, Y.-T, Sim, J.-H, Choi, I.-D, Lee, S.-H, Lee, J.H
• Format: Article
• Language: English
• Subjects: Adult; Aged; Apolipoprotein A-V; Apolipoproteins A - blood; Cardiovascular; Dietary Supplements; Double-Blind Method; Fasting - blood; Fatty Acids - blood; Female; Follow-Up Studies; Humans; Hypertriglyceridemia - blood; Hypertriglyceridemia - diet therapy; Hypertriglyceridemic; Lactobacillus plantarum - classification; Lysopcs; Lysophosphatidylcholines - blood; Male; Middle Aged; Probiotic; Probiotics - administration & dosage; Probiotics - pharmacology; Treatment Outcome; Triglyceride; Triglycerides - blood
• ISSN: 0939-4753; 1590-3729
• DOI: 10.1016/j.numecd.2015.05.002

Abstract Background and aims This study evaluated the triglyceride (TG)-lowering effects of consuming dual probiotic strains of Lactobacillus curvatus ( L. curvatus ) HY7601 and Lactobacillus plantarum ( L. plantarum ) KY1032 on the fasting plasma metabolome. Methods and results A randomized, double-blind, placebo-controlled study was conducted on 92 participants with hypertriglyceridemia but without diabetes. Over a 12-week testing period, the probiotic group consumed 2 g of powder containing 5 × 109  colony-forming units (cfu) of L. curvatus HY7601 and 5 × 109  cfu of L. plantarum KY1032 each day, whereas the placebo group consumed the same product without probiotics. Fasting plasma metabolomes were profiled using UPLC-LTQ-Orbitrap MS. After 12 weeks of treatment, the probiotic group displayed a 20% reduction ( p  = 0.001) in serum TGs and 25% increases ( p = 0.001) in apolipoprotein A-V (apoA-V). At the 12-week follow-up assessment, the following 11 plasma metabolites were significantly reduced in the probiotic group than the placebo group: palmitoleamide, palmitic amide, oleamide, and lysophosphatidyl choline (lysoPC) containing C14:0, C16:1, C16:0, C17:0, C18:3, C18:2, C18:1, and C20:3. In the probiotic group, changes (▵) in TG were negatively correlated with ▵ apoA-V, which was positively correlated with ▵ FFA. In addition, ▵ FFA was strongly and positively correlated with ▵ lysoPCs in the probiotic group but not the placebo group. Conclusions The triglyceride-lowering effects of probiotic supplementation, partly through elevated apoA-V, in borderline to moderate hypertriglyceridemic subjects showed reductions in plasma metabolites, fatty acid primary amides and lysoPCs ( NCT02215694 ; http://www.clinicaltrials.gov ). Clinical trials: NCT02215694 ; http://www.clinicaltrials.gov